RNA viruses have high mutation rates and variants will never end in the same way that flu & common-cold variation continues. The more interesting question is how will our immune systems adapt and will vaccines continue to provide protection against severity of illness at the same time as they apply selective pressure that enhances viral transmissibility?
Of further interest is why Japanese and Taiwan infection and severity rates remain comparatively low and what - if any - role their openness to a certain anti-parasitic, protease inhibiting drug has played in their success.
Also of great interest is why aspiration isn't mandatory in the US to prevent the vaccine from entering the bloodstream (primarily the heart) rapidly and in large quantities.
Many unanswered questions.